We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+17.63%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.7B
AUM Growth
+$43.5M
Cap. Flow
-$109M
Cap. Flow %
-6.45%
Top 10 Hldgs %
43.98%
Holding
67
New
4
Increased
4
Reduced
33
Closed
4
Avg Time Held
3.3 years
Top 10 Avg Time Held
1.6 years
Top 20 Avg Time Held
1.4 years

Top Buys

Rank Stock Value
1
ORKA icon
Oruka Therapeutics
ORKA
+$14.3M
2
BNTX icon
BioNTech
BNTX
+$14.2M
3
RGNX icon
Regenxbio
RGNX
+$3.94M
4
ATXS icon
Astria Therapeutics
ATXS
+$3.46M
5
FDMT icon
4D Molecular Therapeutics
FDMT
+$3.13M

Top Sells

Rank Stock Value
1
KRYS icon
Krystal Biotech
KRYS
+$40.7M
2
FOLD icon
Amicus Therapeutics
FOLD
+$25.6M
3
BPMC icon
Blueprint Medicines
BPMC
+$10.2M
4
KYMR icon
Kymera Therapeutics
KYMR
+$8.21M
5
TRDA icon
Entrada Therapeutics
TRDA
+$7.99M

Sector Composition

Rank Sector Weight
1 Healthcare 97.73%
2 Industrials 2.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABSI icon
26
Absci
ABSI
$1.52B
$31.5M 1.86%
8,253,316
– –
2021 Q3
12 quarters
BSX icon
27
Boston Scientific
BSX
$64B
$27.7M 1.63%
330,873
-59,380
-15% -$4.68M
2023 Q1
6 quarters
CLDX icon
28
Celldex Therapeutics
CLDX
$2.27B
$22.3M 1.32%
657,175
-61,548
-9% -$2.35M
2020 Q2
17 quarters
IDYA icon
29
IDEAYA Biosciences
IDYA
$3.27B
$21.6M 1.27%
681,150
-78,366
-10% -$2.97M
2023 Q4
3 quarters
STTK icon
30
Shattuck Labs
STTK
$555M
$19.6M 1.15%
5,615,489
– –
2020 Q4
15 quarters
BNTX icon
31
BioNTech
BNTX
$22.7B
$18.3M 1.08%
+154,456
New +$14.2M
2024 Q3
0 quarters
IMVT icon
32
Immunovant
IMVT
$5.68B
$18.3M 1.08%
642,229
-77,948
-11% -$2.3M
2022 Q4
7 quarters
FDMT icon
33
4D Molecular Therapeutics
FDMT
$711M
$13.6M 0.8%
1,262,090
+188,655
+18% +$3.13M
2024 Q1
2 quarters
ISRG icon
34
Intuitive Surgical
ISRG
$151B
$13.1M 0.77%
26,698
-13,145
-33% -$6.12M
2023 Q4
3 quarters
SYK icon
35
Stryker
SYK
$112B
$11.8M 0.7%
32,741
-6,742
-17% -$2.33M
2022 Q3
8 quarters
ETNB icon
36
DELISTED
89bio
ETNB
$11.6M 0.68%
1,569,850
-175,806
-10% -$1.48M
2023 Q1
6 quarters
ARDX icon
37
Ardelyx
ARDX
$844M
$11.4M 0.67%
1,660,763
-220,738
-12% -$1.3M
2024 Q1
2 quarters
ESTA icon
38
Establishment Labs
ESTA
$1.83B
$11.3M 0.67%
261,803
+48,779
+23% +$2.12M
2024 Q1
2 quarters
ORKA icon
39
Oruka Therapeutics
ORKA
$4.89B
$10.1M 0.59%
+411,728
New +$14.3M
2024 Q3
0 quarters
PRME icon
40
Prime Medicine
PRME
$655M
$8.03M 0.47%
2,074,350
– –
2022 Q4
7 quarters
ALXO icon
41
ALX Oncology
ALXO
$138M
$6.98M 0.41%
3,836,576
-199,875
-5% -$743K
2020 Q3
16 quarters
NUVB icon
42
Nuvation Bio
NUVB
$1.67B
$6.94M 0.41%
3,031,009
– –
2021 Q1
14 quarters
VERV icon
43
DELISTED
Verve Therapeutics
VERV
$6.7M 0.39%
1,383,366
-80,040
-5% -$465K
2021 Q2
13 quarters
RPTX icon
44
DELISTED
Repare Therapeutics
RPTX
$6.68M 0.39%
1,942,555
– –
2020 Q2
17 quarters
ACIU icon
45
AC Immune
ACIU
$244M
$6.4M 0.38%
1,694,167
-113,537
-6% -$396K
2023 Q4
3 quarters
CYTK icon
46
Cytokinetics
CYTK
$8.89B
$5.13M 0.3%
97,116
-14,751
-13% -$822K
2024 Q1
2 quarters
VTYX icon
47
DELISTED
Ventyx Biosciences
VTYX
$4.59M 0.27%
2,107,215
-56,911
-3% -$131K
2022 Q3
8 quarters
STXS icon
48
Stereotaxis
STXS
$105M
$4.3M 0.25%
2,108,219
– –
2019 Q3
20 quarters
ATRA icon
49
Atara Biotherapeutics
ATRA
$96.9M
$3.68M 0.22%
452,270
– –
2014 Q4
39 quarters
BOLD icon
50
Boundless Bio
BOLD
$54.3M
$3.55M 0.21%
1,023,548
-11,035
-1% -$40K
2024 Q1
2 quarters
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2024 Portfolio in Review

As of Q3 2024, Redmile Group held 67 positions worth $1.7B, up 2.6% from $1.65B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Redmile Group withdrew a net $109M in Q3 2024, closing 4 positions and reducing 33 holdings. Its most notable exit was Blueprint Medicines, an estimated $10.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in Oruka Therapeutics worth $10.1M.

  • Redmile Group's largest Q3 2024 buy was Oruka Therapeutics: 411,728 shares worth $10.1M.
  • Redmile Group added most to Regenxbio in Q3 2024, an estimated $3.94M increase.
  • Redmile Group's biggest Q3 2024 reduction was Krystal Biotech, cutting an estimated $40.7M.
  • Redmile Group fully exited Blueprint Medicines in Q3 2024, selling an estimated $10.2M.
  • Redmile Group's ten largest holdings make up 44% of its $1.7B portfolio in Q3 2024.
  • Redmile Group opened 4 new positions and closed 4 in Q3 2024.
  • Redmile Group's portfolio value rose 2.6% quarter-over-quarter to $1.7B.

Based on Redmile Group's 13F filing for Q3 2024, filed 14 Nov 2024.